H2020 funding for drug response profiling of ovarian cancer
|Funding Program||EU Horizon 2020 Research and Innovation program|
Comprehensive characterization and effective combinatorial targeting of high-grade serous ovarian cancer via single-cell analysis
An international collaboration project to study drug resistance in ovarian cancer has received 6 million euros for five years from the EU Horizon 2020 Research and Innovation program. The project is coordinated from the University of Helsinki, Finland, and began on January 1, 2016. Two FIMM-EMBL group leaders, Krister Wennerberg and Tero Aittokallio, who are both active collaborators in EATRIS platforms, are responsible for a work package on sub-clonal level drug response profiling and modeling.